GlassScriptPhysician profile
Patrick J Dipaolo
NPI 1245341171
$25,843.37
in general payments reported to CMS, 2019-2025
71 companies · $1,716 in 2025
The $1,716 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,552 · 2020: $3,856 · 2021: $4,412 · 2022: $4,133 · 2023: $5,605 · 2024: $3,569 · 2025: $1,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $488 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,235.73 |
| Education | $487.52 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,283.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,428.08 | 2019-2025 | Lynparza, Imfinzi, Tagrisso |
| Incyte Corporation | $2,264.28 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $1,936.54 | 2019-2025 | Reblozyl, Opdivo, Pomalyst |
| Exelixis INC. | $1,718.33 | 2021-2025 | Cabometyx |
| Janssen Biotech, INC. | $1,593.61 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Amgen INC. | $903.81 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Merck Sharp & Dohme LLC | $766.65 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $718.99 | 2019-2025 | |
| Gilead Sciences, INC. | $709.02 | 2019-2025 | Trodelvy |
| Beigene USA, INC. | $510.06 | 2021-2025 | Brukinsa, Tevimbra |
| Pfizer INC. | $508.46 | 2019-2025 | |
| Celgene Corporation | $453.54 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Daiichi Sankyo INC. | $388.12 | 2019-2025 | Enhertu, Injectafer |
| Eisai INC. | $386.46 | 2019-2025 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Dipaolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.